tbuckley/cabot-search huggingface dataset:
Circulating Tumor Cells with Aberrant <i>ALK</i> Copy Number Predict Progression-Free Survival during Crizotinib Treatment in <i>ALK</i>-Rearranged Non–Small Cell Lung Cancer Patients
Authors: Emma Pailler, Marianne Oulhen, Isabelle Borget, Jordi Remon, Kirsty Ross, Nathalie Auger, Fanny Billiot, Maud Ngo Camus, Frédéric Commo, Colin R. Lindsay, David Planchard, Jean-Charles Soria, Benjamin Besse, Françoise Farace
Journal: Cancer Research (2017)

The duration and magnitude of clinical response are unpredictable in ALK-rearranged non-small cell lung cancer (NSCLC) patients treated with crizotinib, although all patients invariably develop resistance. Here, we evaluated whether circulating tumor cells (CTC) with aberrant ALK-FISH patterns [ALK-rearrangement, ALK-copy number gain (ALK-CNG)] monitored on crizotinib could predict progression-free survival (PFS) in a cohort of ALK-rearranged patients. Thirty-nine ALK-rearranged NSCLC patients treated with crizotinib as first ALK inhibitor were recruited prospectively. Blood samples were collected at baseline and at an early time-point (2 months) on crizotinib. Aberrant ALK-FISH patterns were examined in CTCs using immunofluorescence staining combined with filter-adapted FISH after filtration enrichment. CTCs were classified into distinct subsets according to the presence of ALK-rearrangement and/or ALK-CNG signals. No significant association between baseline numbers of ALK-rearranged or ALK-CNG CTCs and PFS was observed. However, we observed a significant association between the decrease in CTC number with ALK-CNG on crizotinib and a longer PFS (likelihood ratio test, P = 0.025). In multivariate analysis, the dynamic change of CTC with ALK-CNG was the strongest factor associated with PFS (HR, 4.485; 95% confidence interval, 1.543-13.030, P = 0.006). Although not dominant, ALK-CNG has been reported to be one of the mechanisms of acquired resistance to crizotinib in tumor biopsies. Our results suggest that the dynamic change in the numbers of CTCs with ALK-CNG may be a predictive biomarker for crizotinib efficacy in ALK-rearranged NSCLC patients. Serial molecular analysis of CTC shows promise for real-time patient monitoring and clinical outcome prediction in this population. Cancer Res; 77(9); 2222-30. ©2017 AACR.
Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases
Authors: Helen Ha, Bikash Debnath, Nouri Neamati
Journal: Theranostics (2017)

The chemokine receptors CXCR1/2 and their ligand CXCL8 are essential for the activation and trafficking of inflammatory mediators as well as tumor progression and metastasis. The CXCL8-CXCR1/2 signaling axis is involved in the pathogenesis of several diseases including chronic obstructive pulmonary diseases (COPD), asthma, cystic fibrosis and cancer. Interaction between CXCL8 secreted by select cancer cells and CXCR1/2 in the tumor microenvironment is critical for cancer progression and metastasis. The CXCL8-CXCR1/2 axis may play an important role in tumor progression and metastasis by regulating cancer stem cell (CSC) proliferation and self-renewal. During the past two decades, several small-molecule CXCR1/2 inhibitors, CXCL8 releasing inhibitors, and neutralizing antibodies against CXCL8 and CXCR1/2 have been reported. As single agents, such inhibitors are expected to be efficacious in various inflammatory diseases. Several preclinical studies suggest that combination of CXCR1/2 inhibitors along with other targeted therapies, chemotherapies, and immunotherapy may be effective in treating select cancers. Currently, several of these inhibitors are in advanced clinical trials for COPD, asthma, and metastatic breast cancer. In this review, we provide a comprehensive analysis of the role of the CXCL8-CXCR1/2 axis and select genes co-expressed in this pathway in disease progression. We also discuss the latest progress in developing small-molecule drugs targeting this pathway.
European evidence-based recommendations for diagnosis and treatment of paediatric antiphospholipid syndrome: the SHARE initiative
Authors: Noortje Groot, Nienke de Graeff, Tadej Avcin, Brigitte Bader-Meunier, Pavla Dolezalova, Brian Feldman, Gili Kenet, Isabelle Koné-Paut, Pekka Lahdenne, Stephen D Marks, Liza McCann, Clarissa A Pilkington, Angelo Ravelli, Annet van Royen-Kerkhof, Yosef Uziel, Sebastiaan J Vastert, Nico M Wulffraat, Seza Ozen, Paul Brogan, Sylvia Kamphuis, Michael W Beresford
Journal: Annals of the Rheumatic Diseases (2017)

Antiphospholipid syndrome (APS) is rare in children, and evidence-based guidelines are sparse. Consequently, management is mostly based on observational studies and physician’s experience, and treatment regimens differ widely. The Single Hub and Access point for paediatric Rheumatology in Europe (SHARE) initiative was launched to develop diagnostic and management regimens for children and young adults with rheumatic diseases. Here, we developed evidence-based recommendations for diagnosis and treatment of paediatric APS. Evidence-based recommendations were developed using the European League Against Rheumatism standard operating procedure. Following a detailed systematic review of the literature, a committee of paediatric rheumatologists and representation of paediatric haematology with expertise in paediatric APS developed recommendations. The literature review yielded 1473 articles, of which 15 were valid and relevant. In total, four recommendations for diagnosis and eight for treatment of paediatric APS (including paediatric Catastrophic Antiphospholipid Syndrome) were accepted. Additionally, two recommendations for children born to mothers with APS were accepted. It was agreed that new classification criteria for paediatric APS are necessary, and APS in association with childhood-onset systemic lupus erythematosus should be identified by performing antiphospholipid antibody screening. Treatment recommendations included prevention of thrombotic events, and treatment recommendations for venous and/or arterial thrombotic events. Notably, due to the paucity of studies on paediatric APS, level of evidence and strength of the recommendations is relatively low. The SHARE initiative provides international, evidence-based recommendations for diagnosis and treatment for paediatric APS, facilitating improvement and uniformity of care.
Results from a Hemato-Oncology Latin America Observational Registry (HOLA) Providing Real World Outcomes for the Treatment of Patients with NHL
Authors: Miguel A Pavlovsky, Laura Fogliatto, Gladys Patricia Agreda Vásquez, Alicia Enrico, María Jose Mela Osorio, Jorge Antonio Armenta San-Sebastian, Roberto Ovilla, Oscar Avendaño, Lineth López, Telma Santos, Odin De La Mora Estrada
Journal: Blood (2016)
Implications and Interpretations of Differences in Age-Adjusted Testosterone Levels—Reply
Authors: Halis Kaan Akturk, Todd B. Nippoldt
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease
Authors: Rohit Loomba, Victor Seguritan, Weizhong Li, Tao Long, Niels Klitgord, Archana Bhatt, Parambir Singh Dulai, Cyrielle Caussy, Richele Bettencourt, Sarah K. Highlander, Marcus B. Jones, Claude B. Sirlin, Bernd Schnabl, Lauren Brinkac, Nicholas Schork, Chi-Hua Chen, David A. Brenner, William Biggs, Shibu Yooseph, J. Craig Venter, Karen E. Nelson
Journal: Cell Metabolism (2017)
The Complex and Multifaceted Aspects of Conflicts of Interest
Authors: William W. Stead
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Examination of the role of integrin β3 in chemoresistance by analysis of residual NACT tumor specimens and knock-in experiments
Authors: M.G. Nair, J.S. Prabhu, J. Remacle, H.P. S, A. Korlimarla, R.S. Kaluve, A. Alexander, S. Patil, S.B. S, S.T. Srinivas
Journal: Annals of Oncology (2017)
F<scp>ifty</scp> Y<scp>ears</scp> <scp>of</scp> R<scp>esearch</scp> <scp>in</scp> ARDS.Is Extracorporeal Circulation the Future of Acute Respiratory Distress Syndrome Management?
Authors: Alain Combes, Antonio Pesenti, V. Marco Ranieri
Journal: American Journal of Respiratory and Critical Care Medicine (2017)

Section:ChooseTop of pageAbstract <<Function of the Membrane ...How Membrane Lung Can Sup...Historical Studies of Ext...More Recent Studies of Ex...Rationale for Applying EC...ECLS as Rescue Therapy fo...ECLS to Minimize/Abolish ...Patients Management under...Center Organization for S...ConclusionsReferencesCITING ARTICLES
Characteristics and Outcome of Direct Antiglobulin Test-Negative Hemolytic Anemia: A Case Series
Authors: Aishwarya Ravindran, Janani Sankaran, Min Shi, Eapen K. Jacob, Justin D. Kreuter, Jeffrey L. Winters, C. Christopher Hook, Timothy G. Call, Ariela L. Marshall, Rajiv K. Pruthi, Aneel A. Ashrani, Kebede H. Begna, Neil E. Kay, Ronald S. Go
Journal: Blood (2016)
Re: Vladimir Student Jr., Ales Vidlar, Michal Grepl, Igor Hartmann, Eva Buresova, Vladimir Student. Advanced Reconstruction of Vesicourethral Support (ARVUS) during Robot-assisted Radical Prostatectomy: One-year Functional Outcomes in a Two-group Randomised Controlled Trial. Eur Urol 2017;71:822–30
Authors: Fabrizio Dal Moro
Journal: European Urology (2017)
Epigenetic down regulation of G protein-coupled estrogen receptor (GPER) functions as a tumor suppressor in colorectal cancer
Authors: Qiao Liu, Zhuojia Chen, Guanmin Jiang, Yan Zhou, Xiangling Yang, Hongbin Huang, Huanliang Liu, Jun Du, Hongsheng Wang
Journal: Molecular Cancer (2017)

Estrogenic signals are suggested to have protection roles in the development of colorectal cancer (CRC). The G protein-coupled estrogen receptor (GPER) has been reported to mediate non-genomic effects of estrogen in hormone related cancers except CRC. Its expression and functions in CRC were investigated.The expression of GPER and its associations with clinicopathological features were examined. The mechanisms were further investigated using cells, mouse xenograft models, and clinical human samples.GPER was significantly (p < 0.01) down regulated in CRC tissues compared with their matched adjacent normal tissues in our two cohorts and three independent investigations from Oncomine database. Patients whose tumors expressing less (n = 36) GPER showed significant (p < 0.01) poorer survival rate as compared with those with greater levels of GPER (n = 54). Promoter methylation and histone H3 deacetylation were involved in the down regulation of GPER in CRC cell lines and clinical tissues. Activation of GPER by its specific agonist G-1 inhibited proliferation, induced cell cycle arrest, mitochondrial-related apoptosis and endoplasmic reticulum (ER) stress of CRC cells. The upregulation of reactive oxygen species (ROS) induced sustained ERK1/2 activation participated in G-1 induced cell growth arrest. Further, G-1 can inhibit the phosphorylation, nuclear localization, and transcriptional activities of NF-κB via both canonical IKKα/ IκBα pathways and phosphorylation of GSK-3β. Xenograft model based on HCT-116 cells confirmed that G-1 can suppress the in vivo progression of CRC.Epigenetic down regulation of GPER acts as a tumor suppressor in colorectal cancer and its specific activation might be a potential approach for CRC treatment.
Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis
Authors: Francesca Gorini, Laura Azzimonti, Gloria Delfanti, Lydia Scarfò, Cristina Scielzo, Maria Teresa Bertilaccio, Pamela Ranghetti, Alessandro Gulino, Claudio Doglioni, Arianna Di Napoli, Miriam Capri, Claudio Franceschi, Federico Caligaris-Cappio, Paolo Ghia, Matteo Bellone, Paolo Dellabona, Giulia Casorati, Claudia de Lalla
Journal: Blood (2017)
Proposed Definition of Necrotizing Enterocolitis May Be of Limited Value—Reply
Authors: Neena Modi, Cheryl Battersby, Nick Longford
Journal: JAMA Pediatrics (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Lenalidomide Maintenance after Autologous Stem Cell Transplant in Patients with High-Risk Relapsed/Refractory Lymphomas Is Feasible and Compares Favorably to Historical Controls: Results of a Phase I/II Trial
Authors: Jakub Svoboda, Lauren E. Strelec, Daniel J. Landsburg, Sunita Dwivedy Nasta, Anthony R. Mato, Wei-Ting Hwang, Sarah Jordan Nagle, Elise A. Chong, Samantha Garrett, Terease S. Waite, Ellen Napier, Stephen J. Schuster
Journal: Blood (2016)
Biliary Tract and Liver Complications in Polycystic Kidney Disease
Authors: Parminder K. Judge, Charlie H.S. Harper, Benjamin C. Storey, Richard Haynes, Martin J. Wilcock, Natalie Staplin, Raph Goldacre, Colin Baigent, Jane Collier, Michael Goldacre, Martin J. Landray, Christopher G. Winearls, William G. Herrington
Journal: Journal of the American Society of Nephrology (2017)

Polycystic liver disease is a well described manifestation of autosomal dominant polycystic kidney disease (ADPKD). Biliary tract complications are less well recognized. We report a 50-year single-center experience of 1007 patients, which raised a hypothesis that ADPKD is associated with biliary tract disease. We tested this hypothesis using all England Hospital Episode Statistics data (1998–2012), within which we identified 23,454 people with ADPKD and 6,412,754 hospital controls. Hospitalization rates for biliary tract disease, serious liver complications, and a range of other known ADPKD manifestations were adjusted for potential confounders. Compared with non-ADPKD hospital controls, those with ADPKD had higher rates of admission for biliary tract disease (rate ratio [RR], 2.24; 95% confidence interval [95% CI], 2.16 to 2.33) and serious liver complications (RR, 4.67; 95% CI, 4.35 to 5.02). In analyses restricted to those on maintenance dialysis or with a kidney transplant, RRs attenuated substantially, but ADPKD remained associated with biliary tract disease (RR, 1.19; 95% CI, 1.08 to 1.31) and perhaps with serious liver complications (RR, 1.15; 95% CI, 0.98 to 1.33). The ADPKD versus non-ADPKD RRs for biliary tract disease were larger for men than women (heterogeneity P &lt;0.001), but RRs for serious liver complications appeared higher in women (heterogeneity P &lt;0.001). Absolute excess risk of biliary tract disease associated with ADPKD was larger than that for serious liver disease, cerebral aneurysms, and inguinal hernias but less than that for urinary tract infections. Overall, biliary tract disease seems to be a distinct and important extrarenal complication of ADPKD.
One-year overall survival (OS) and biomarker correlates from a phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM).
Authors: Rahima Jamal, Leon Van Kempen, Pamela Thebault, Karl Belanger, Jennifer Elisabeth Friedmann, Jean-Pierre M. Ayoub, Eftihia Cocolakis, Shirin Kazemi, Jeanne Dionne, Caroline Lambert, HB Le, Cecile Grange, Jean-Francois Cailhier, Alan Spatz, Rejean Lapointe, Wilson H. Miller
Journal: Journal of Clinical Oncology (2015)

9062 Background: Pivotal studies with IPI demonstrated increased OS both as single agent (10.1 months) and with DTIC (11.2 months). We’ve previously reported an encouraging safety profile with IPI plus CP and early efficacy results. We now report updated 1-year OS and biomarker correlates of patient response. Methods: 30 patients were randomized in a 1:2 ratio to arm A (C (AUC = 6) and P (175mg/m2) every 3 weeks x 5 and IPI (3mg/kg) every 3 weeks x 4 starting at week 4) or arm B (similar dosing to arm A except IPI was given on week after CP). Tumor biopsies were collected at screening and week 8, and immune monitoring bloods were collected throughout. Results: Median OS was 16.1 months, with a 1-year OS of 56.5% for all patients with no differences between arms. Overall median follow-up was 23.2 months. Best overall response rate (BORR) and disease control rate (DCR) were 26.7% and 56.7% by irRC. BORR in patients whose tumors were wild type for BRAF and NRAS was 44%, compared to 8% in patients with a mutation in BRAF or NRAS. Clinical responses correlated with the abundance of peri and intratumoral CD3+ inflammatory cells in the pretreatment biopsy, but not with CD4/CD8 ratios or CD20 infiltrate. Circulating levels of some chemokines were elevated in non-responders compared to responders. While IPI influenced B cells and monocyte differentiation, this did not correlate with clinical outcome. Although all patients had an increase in ICOS+ T cells after IPI treatment, a pre-existing low proportion of ICOS+ T cells before treatment was associated with a more favorable clinical outcome. Lower levels of PD-1 on CD4 and CD8 T cells were observed in responders compared to non-responders. Conclusions: Median OS and 1-year OS compared favorably to previous pivotal trials. Patients whose tumors were wild type for BRAF/NRAS had a higher rate of objective response. High baseline level of CD3 infiltrate was associated with a positive clinical response to IPI/CP. A low activation state (ICOS) before treatment and maintenance of low levels of PD-1 on T cells during treatment correlated to a favorable clinical response to IPI. Clinical trial information: NCT01676649.
The MEK/ERK Inhibitor Trametinib Reduces Fibrosis in a Transduction-Transplantation Model of Mutated Calreticulin
Authors: Thanh Kim Nguyen, Prasanthi Tata, Stefan Brooks, Nilamani Jena, Sarah J Morse, Zhong-ying Liu, Hew Yeng Lai, Sherif Rezk, Richard A. Van Etten, Angela G Fleischman
Journal: Blood (2016)
A New Green Titania with Enhanced NIR Absorption for Mitochondria-Targeted Cancer Therapy
Authors: Juan Mou, Tianquan Lin, Fuqiang Huang, Jianlin Shi, Hangrong Chen
Journal: Theranostics (2017)

A new kind of green titania (G-TiO 2-x ) with obvious green color was facilely synthesized from black titania (B-TiO 2-x ) through subsequently strong ultrasonication.Comparatively, this stable G-TiO 2-x shows much enhanced near infrared (NIR) absorption, especially around 920 nm, which can be ascribed to the obvious change of TiO 2-x lattice order owing to the effect of ultrasonication.This feature enables G-TiO 2-x to be stimulated with 980 nm laser in the combined photodynamic therapy (PDT) and photothermal therapy (PTT), which is greatly beneficial for improving tissue penetration depth.Furthermore, since mitochondria are preferred subcellular organelles for PDT/PTT, G-TiO 2-x was further designed to conjugate with triphenylphosphonium (TPP) ligand for mitochondria-targeted PDT/PTT to obtain precise cancer treatment.Attributing to the high mitochondria-targeting efficiency and simultaneously synergistic PDT/PTT, high phototherapeutic efficacy and safety with a much lower laser power density (980 nm, 0.72 W cm -2 ) and low materials dosage were achieved both in vitro and in vivo.In addition, negligible toxicity was found, indicating high biocompatibility.This novel G-TiO 2-x could provide new strategies for future precise minimal/non-invasive tumor treatment.
Annals Story Slam - Summertime and the Living Is Easy
Authors: Jerry Johnson
Journal: Annals of Internal Medicine (2017)

Web Exclusives2 May 2017Annals Story Slam - Summertime and the Living Is EasyFREEJerry Johnson, MDJerry Johnson, MDFrom University of Pennsylvania, Philadelphia, Pennsylvania.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/W17-0043 SectionsAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Video. Annals Story Slam - Summertime and the Living Is Easy "Summertime and the Living Is Easy," by Dr. Jerry Johnson (Duration 8:04)Building on the popular Annals feature “On Being a Doctor,” storytellers share stories about the experience of doctoring on video.For more videos from and information on Annals Story Slam, visit go.annals.org/StorySlam. Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: From University of Pennsylvania, Philadelphia, Pennsylvania.Current Author Address: Jerry Johnson, MD, University of Pennsylvania, Philadelphia, PA; e-mail, [email protected]med.upenn.edu. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 2 May 2017Volume 166, Issue 9Page: SS1 ePublished: 2 May 2017 Issue Published: 2 May 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.Loading ...